Haematological Malignancy research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - active not recruiting
Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study
This study looks at health problems, especially cancer, after organ transplants in the UK. Researchers are combining existing patient information to better understand why cancer happens and how it affects people after a transplant, to help improve care.
United Kingdom - recruitingNA
Feasibility of Ambulatory Talc. Pleurodesis
This study looks at treating fluid build-up around the lungs caused by cancer, usually needing a hospital stay. We're exploring if this treatment can be done at home, to improve patients' comfort and quality of life.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom